NewLink Genetics Announces Presentation of Two Abstracts at ASCO

World News: . []

AMES, Iowa, April 21, 2017 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The complete text of the abstracts will be posted online at 5:00 p.m. ET on Wednesday, May 17.

NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer.  For more information, please visit .

Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
(515) 598-2555
lmiller@linkp.com

Investor Contact:
Beth Kurth, VP
LaVoieHealthScience
(617) 374-8800, ext. 106
bkurth@lavoiehealthscience.com

Media Contact:
Sharon Correia, VP
LaVoieHealthScience
(617) 374-8800, ext. 105
scorreia@lavoiehealthscience.com

More news and information about NewLink Genetics Corporation

Published By:

Globe Newswire: 12:00 GMT Friday 21st April 2017

Published: .

Search for other references to "newlink" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers